PSMA PET in this setting will be helpful in detecting the tumour foci and subsequently guiding a targeted biopsy, particularly in patients with negative (Prostate Imaging-Reporting and Data System, PIRADS 1 or 2) or inconclusive (PIRADS 3) mpMRI findings and clinical or biochemical features highly suggestive of PCa, hence increases the diagnostic accuracy (Figure 1). This evidence concerns the gene FOLH1 and neoplasm.